Saratin is a 12 kDa polypeptide originally identified as a component of leech saliva (Hirudo medicinalis) and currently produced as a recombinant protein in yeast (Hansenula polymorpha).

Saratin is designed to be applied during surgery to the endovascular surface where it coats the exposed collagen and inhibits vWF-dependent binding of platelets to arterial wall collagens.  In preventing the vWF-mediated platelet adhesion to damaged vessels, saratin blocks the first step in a sequence of events involving platelet aggregation and activation and may thereby prevent the subsequent thrombus formation and intimal hyperplasia that occurs in a range of vascular surgical and endovascular procedures.

The results of pre-clinical studies of our product candidates may not be predictive of the results of clinical trials.  Product candidates in early clinical trials and later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies.


Below are links for two mechanism of action movies

What we treat

How we treat it



Saratin Publications

  1. Barnes, CS, Krafft, B, Frech, M, Hofmann, UR, Papendieck, A, Dahlems, U, Gellissen, G and Hoylaerts, MF.  Production and Characterization of Saratin, an Inhibitor of von Willebrand Factor-Dependent Platelet Adhesion to Collagen. Sem. Thromb. Hemost. 2001;24(4)337-347.
  2. Bonnefoy, A, Romijn, RAP, Vandervoort, PAH, Rompaey, IV, Vermylen, J and Hoylaerts, F.  Von Willebrand Factor A1 Domain Can Adequately Substitute for A3 Domain in Recruitment of Flowing Platelets to Collagen. Thromb. Haemost., 2006;4:1-11.
  3. Vilahur, G, Duran, X, Juan-Babot, O, Casani, L, and Badimon, L.  Antithrombotic Effects of Saratin on Human Atherosclerotic Plaques. Thromb. Haemost. 2004;92:191-200.
  4. Cruz, CP, Eidt, J, Drouilhet, J, Brown, AT,Wang, Y, Barnes CS, and Moursi, MM.   Saratin, and Inhibitor of von Willebrand Factor-Dependent Platelet Adhesion, Decreases Platelet Aggregation and Intimal Hyperplasia in a Rat Carotid Endarterectomy Model. J. Vasc. Surg 2001;34:724-729.
  5. Davis, JA, Brown, AT, Alshafie, T, Poirier, LA, Cruz CP, Wang, Y, Eidt, JF and Moursi, MM.  Saratin (an Inhibitor of Platelet-Collagen Interaction) Decreases Platelet Aggregation and Homocysteine-Mediated Postcarotid Endarterectomy Intimal Hyperplasia in a Dose-Dependent Manner. Am. J. Surg. 2004;188:778-785.
  6. Smith, TP, Alshafie, TA, Cruz, CP, Fan, CY, Brown, AT, Wang, Y, Eidt, JF and Moursi, MM.  Saratin, an Inhibitor of collagen-Platelet Interaction, Decreases Venous Anastomotic Intimal Hyperplasia in a canine Dialysis Access Model.  Vasc. Endovasc. Surg. 2003;37:259-269.


Website design: Evenayr Graphics, Portland Oregon,